VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017 05 11; 129(19):2612-2615.
View in:
PubMed
subject areas
Adenine
Antineoplastic Agents
Disease-Free Survival
Dose-Response Relationship, Drug
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Mutation
Patient Compliance
Piperidines
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Pyrazoles
Pyrimidines
Tumor Suppressor Protein p53
authors with profiles
JAN ANDREAS BURGER